Category: Gene Therapies

Cell and Gene Therapy CROs: The Next Growth Opportunity

Over the years, cell and gene therapy (CGT) and other advanced therapy medicinal products (ATMPs) have managed to capture the interest of both drug developers and healthcare investors. Their popularity can be attributed to various factors, such as minimal side effects, clinical efficacy and their personalized nature. However, there are several complexities associated with the

Non Viral Transfection Reagent: Market Landscape and Key Trends

In order to manipulate the cells, genetic material / nucleic acid is artificially introduced into the cells by using specific carriers / vectors. This process is known as transfection. It does not use viral components for transfection and are aimed at circumventing the challenges, such as inflammation, immunogenicity and non-specific transduction, associated with viral vectors.

Bioassay Services – A Prerequisite for the ATMPs Development

Bioassay Services – A Prerequisite for the Cell and Gene Therapy Development Over the past few years, investigational new drug (IND) filings by cell and gene therapy companies have significantly increased. In fact, from year 2016 to 2020 more than 300 IND filing for cell and gene therapy product have been recorded, indicating that several

Gene Therapy Companies: 10 Key Facts

Gene therapy companies have emerged as the savior in offering sophisticated products to treat patients with defective genes and chronic diseases. There are two types of gene therapies on the basis of targeted gene location: germline gene therapy and somatic gene therapy. These therapies are implemented to treat several diseases, such as hemophilia, Parkinson’s, Alzheimer’s,